19 jam - Menerjemahkan

Tuberculosis Combination Shows Early Activity In Phase Two Trial

BioVersys has reported results from a Phase two a trial of a tuberculosis combination containing AlpE in patients with newly diagnosed drug sensitive pulmonary tuberculosis. The ENABLE study tested alpibectir at forty five milligrams combined with ethionamide at two doses over fourteen days. All regimens showed early bactericidal activity and the higher ethionamide arm performed better than the lower dose arm. When AlpE was combined with rifampicin pyrazinamide and ethambutol the early activity was comparable to standard HRZE care over the same period. Researchers say the result supports further testing of the combination as a potential new option for tuberculosis. Tuberculosis remains a major global health threat and shorter or more effective regimens are urgently needed. The team will now plan longer studies to check safety and cure rates.

image
advertisement
"We will never ask you to login, or register through a third-party advertisement."